The validity of the anti-PD-L1 antibody was evaluated by its ability to detect the decrease of PD-L1 levels after siRNA knockdown of this ligand and the increase in expression of PD-L1 upon treatment of two gastric cancer cell lines (AGS and NCI-n87) with IFN-γ. This evidence concerns the gene IFNG and gastric cancer.